Standard BioTools Inc.
LAB
$1.50
$0.074.90%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 14.65% | 13.40% | 8.40% | 7.02% | -9.54% |
| Total Other Revenue | -- | -- | -- | -6.02% | 156.55% |
| Total Revenue | 14.65% | 13.40% | 8.40% | 6.21% | -10.23% |
| Cost of Revenue | 6.94% | -0.12% | 1.56% | 15.45% | 100.24% |
| Gross Profit | 29.23% | 41.52% | 21.24% | -6.76% | -56.05% |
| SG&A Expenses | 25.77% | 26.40% | 25.99% | 29.46% | 12.36% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.79% | 18.80% | 19.03% | 22.03% | 7.07% |
| Operating Income | -28.14% | -25.65% | -34.52% | -48.70% | -39.14% |
| Income Before Tax | -30.01% | -17.91% | -41.37% | -31.12% | -11.19% |
| Income Tax Expenses | -1,648.15% | -945.00% | 2.65% | 19.91% | -84.21% |
| Earnings from Continuing Operations | -27.84% | -17.44% | -41.21% | -31.05% | -10.32% |
| Earnings from Discontinued Operations | 47.74% | 34.86% | -77.46% | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.94% | -1.56% | -47.56% | -86.03% | -64.53% |
| EBIT | -28.14% | -25.65% | -34.52% | -48.70% | -39.14% |
| EBITDA | -48.03% | -45.12% | -48.91% | -54.26% | -32.32% |
| EPS Basic | 52.28% | 64.50% | 64.34% | 41.45% | 25.93% |
| Normalized Basic EPS | 22.13% | 54.59% | 64.04% | 69.43% | 54.23% |
| EPS Diluted | 52.61% | 64.87% | 64.68% | 42.04% | 25.77% |
| Normalized Diluted EPS | 22.13% | 54.59% | 64.04% | 69.43% | 54.23% |
| Average Basic Shares Outstanding | 35.63% | 82.33% | 181.50% | 346.12% | 253.34% |
| Average Diluted Shares Outstanding | 35.63% | 82.33% | 181.50% | 346.12% | 253.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |